SW
JAZZ icon

SVB Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

SVB Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-290
Closed -$36K – 1061
2025
Q1 		$36K Buy
+290
New +$37.8K ﹤0.01% 611
2016
Q4 		– Sell
-2,084
Closed -$253K – 509
2016
Q3 		$253K Sell
2,084
-777
-27% -$105K 0.01% 461
2016
Q2 		$404K Sell
2,861
-78
-3% -$11.5K 0.02% 382
2016
Q1 		$384K Buy
2,939
+61
+2% +$7.59K 0.02% 395
2015
Q4 		$405K Sell
2,878
-1,428
-33% -$198K 0.02% 406
2015
Q3 		$572K Buy
4,306
+642
+18% +$111K 0.02% 388
2015
Q2 		$645K Buy
3,664
+140
+4% +$25.1K 0.02% 387
2015
Q1 		$609K Sell
3,524
-20
-0.6% -$3.43K 0.02% 385
2014
Q4 		$580K Buy
+3,544
New +$588K 0.02% 382

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

SVB Wealth's JAZZ Position: Q2 2025 in Review

SVB Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 290 shares — an estimated $36K sold.

SVB Wealth first reported a position in JAZZ in Q4 2014 and held it in 9 quarters. The position peaked at $645K in Q2 2015. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • SVB Wealth reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • SVB Wealth sold 290 Jazz Pharmaceuticals shares in Q2 2025, an estimated $36K.
  • SVB Wealth first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 9 quarters.
  • SVB Wealth's Jazz Pharmaceuticals position peaked at $645K in Q2 2015.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.